March 18 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS ENTERS AGREEMENT WITH INOTIV TO CONDUCT PRECLINICAL TOXICITY STUDIES FOR ITS COVID-T™ IMMUNODIAGNOSTIC PROGRAM
* BIOVAXYS TECHNOLOGY CORP - ANTICIPATES THAT PRECLINICAL TOXICITY STUDY RESULTS WILL BE AVAILABLE EARLY SUMMER
* BIOVAXYS TECHNOLOGY CORP - INTENDS TO SUBMIT ITS PRE-IND MEETING REQUEST TO FDA FOR COVID-T EARLY NEXT MONTH